Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

SELL
$18.5 - $28.14 $214,063 - $325,607
-11,571 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$17.99 - $24.65 $208,162 - $285,225
11,571 New
11,571 $269,000
Q4 2018

Feb 14, 2019

SELL
$13.88 - $21.75 $206,812 - $324,075
-14,900 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$12.46 - $21.74 $185,654 - $323,926
14,900 New
14,900 $324,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Blue Crest Capital Management LTD Portfolio

Follow Blue Crest Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Blue Crest Capital Management LTD with notifications on news.